About
7
Publications
1,507
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
126
Citations
Introduction
Leonor S. Castro graduated in Biochemistry in 2014 by University of Beira Interior (UBI), and finished her MSc in Molecular Biotechnology in 2016 by University of Aveiro. Currently, she is a researcher (MSc Fellowship) at CICECO-UA under the scope of the project IL2BioPro where she is using ionic liquids as phase-forming components of aqueous biphasic systems, envisaging the downstream processing of protein-based biopharmaceuticals.
Current institution
Publications
Publications (7)
Surtos, epidemias e pandemias são responsáveis por grandes alterações económicas, políticas, e sociais, permitindo igualmente um elevado desenvolvimento científico e tecnológico. Ao longo da história, estes eventos têm-se vindo a intensificar devido ao aumento na mobilidade entre populações, o que se traduz num aumento das cadeias de transmissão de...
Immunoglobulin Y (IgY) represents an important class of antibodies, being present in egg yolk, with relevant medical applications and involving non-invasive methods of extraction. However, due to the complexity of egg yolk, the purification levels required for use in most medical applications demands the application of multi-step and cost-intensive...
Novel liquid supports for enzyme immobilization and reuse based on aqueous biphasic systems (ABS) constituted by cholinium‐based ionic liquids (ILs) and polymers for the degradation of dyes are here proposed. The biocatalytic reaction for dye decolorization using laccase occured in the biphasic medium, with the enzyme being “supported” in the IL‐ri...
The advent of biopharmaceuticals in modern medicine brought enormous benefits to the treatment of numerous human diseases and improved the well-being of many people worldwide. First introduced in the market in the early 1980s, the number of approved biopharmaceutical products has been steadily increasing, with therapeutic proteins, antibodies, and...
Protein biopharmaceuticals, among which interferon alpha-2b (IFNα-2b) that can be used in the treatment of chronic hepatitis C and hairy cell leukemia, have become an indispensable product of current medicine. However, their current high costs derived from the lack of cost-effective downstream strategies still limits their widespread use. Polymer-b...
The advent of biopharmaceuticals in modern medicine has brought enormous benefi ts to treat chronic and life-threatening diseases while improving the well-being of humans. Proteins (including antibodies) represent a large fraction of the biopharmaceuticals market, but are still amongst the costliest options due to the lack of cost-eff ective purifi...
